Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Male Hypogonadism Overview 9 Therapeutics Development 10 Pipeline Products for Male Hypogonadism - Overview 10 Pipeline Products for Male Hypogonadism - Comparative Analysis 11 Male Hypogonadism - Therapeutics under Development by Companies 12 Male Hypogonadism - Therapeutics under Investigation by Universities/Institutes 14 Male Hypogonadism - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Male Hypogonadism - Products under Development by Companies 19 Male Hypogonadism - Products under Investigation by Universities/Institutes 20 Male Hypogonadism - Companies Involved in Therapeutics Development 21 Antares Pharma, Inc. 21 Clarus Therapeutics, Inc. 22 Diurnal Limited 23 EndoCeutics, Inc. 24 Ferring International Center S.A. 25 Forendo Pharma Limited 26 Lipocine Inc. 27 M et P Pharma AG 28 Merck & Co., Inc. 29 Mereo Biopharma Group Limited 30 Millennium Pharmaceuticals, Inc. 31 Monosol Rx, LLC 32 Pantarhei Bioscience BV 33 Repros Therapeutics Inc. 34 Variant Pharmaceuticals, Inc. 35 Male Hypogonadism - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 BGS-649 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 corifollitropin alfa - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 enclomiphene citrate - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 fispemifene - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Kisspeptin-10 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Libidua - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 LPCN-1111 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 MSS-722 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 T-2 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 TAK-448 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Testavan - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 testosterone - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 testosterone - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 testosterone - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 testosterone - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 testosterone - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 testosterone enanthate - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 testosterone undecanoate - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 testosterone undecanoate - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 testosterone undecanoate - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 testosterone undecanoate - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 testosterone undecanoate - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 VAR-100 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Male Hypogonadism - Recent Pipeline Updates 78 Male Hypogonadism - Dormant Projects 103 Male Hypogonadism - Discontinued Products 104 Male Hypogonadism - Product Development Milestones 105 Featured News & Press Releases 105 Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men 105 Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism 106 Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference and Provide Update on Fispemifene 106 Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company 106 Jan 07, 2016: Acerus Receives Health Canada Approval For NATESTO 106 Jan 04, 2016: Repros Updates Enclomiphene Program 107 Jan 04, 2016: Lipocine Announces First Patient Dosed in Phase 2B Clinical Study for LPCN 1111, a Novel Testosterone Replacement Therapy 108 Jan 04, 2016: Acerus Announces NATESTO Publication in Prominent Andrology Journal 108 Dec 07, 2015: Transdermal Delivery Solutions Announces Commencement of Clinical Trials of Hormone Replacement Technologies Testagen HypoSpray 109 Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene 109 Appendix 110 Methodology 110 Coverage 110 Secondary Research 110 Primary Research 110 Expert Panel Validation 110 Contact Us 110 Disclaimer 111

List of Tables Number of Products under Development for Male Hypogonadism, H1 2016 10 Number of Products under Development for Male Hypogonadism - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Comparative Analysis by Unknown Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Investigation by Universities/Institutes, H1 2016 20 Male Hypogonadism - Pipeline by Antares Pharma, Inc., H1 2016 21 Male Hypogonadism - Pipeline by Clarus Therapeutics, Inc., H1 2016 22 Male Hypogonadism - Pipeline by Diurnal Limited, H1 2016 23 Male Hypogonadism - Pipeline by EndoCeutics, Inc., H1 2016 24 Male Hypogonadism - Pipeline by Ferring International Center S.A., H1 2016 25 Male Hypogonadism - Pipeline by Forendo Pharma Limited, H1 2016 26 Male Hypogonadism - Pipeline by Lipocine Inc., H1 2016 27 Male Hypogonadism - Pipeline by M et P Pharma AG, H1 2016 28 Male Hypogonadism - Pipeline by Merck & Co., Inc., H1 2016 29 Male Hypogonadism - Pipeline by Mereo Biopharma Group Limited, H1 2016 30 Male Hypogonadism - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 31 Male Hypogonadism - Pipeline by Monosol Rx, LLC, H1 2016 32 Male Hypogonadism - Pipeline by Pantarhei Bioscience BV, H1 2016 33 Male Hypogonadism - Pipeline by Repros Therapeutics Inc., H1 2016 34 Male Hypogonadism - Pipeline by Variant Pharmaceuticals, Inc., H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Stage and Target, H1 2016 38 Number of Products by Stage and Mechanism of Action, H1 2016 40 Number of Products by Stage and Route of Administration, H1 2016 42 Number of Products by Stage and Molecule Type, H1 2016 44 Male Hypogonadism Therapeutics - Recent Pipeline Updates, H1 2016 78 Male Hypogonadism - Dormant Projects, H1 2016 103 Male Hypogonadism - Discontinued Products, H1 2016 104 List of Figures Number of Products under Development for Male Hypogonadism, H1 2016 10 Number of Products under Development for Male Hypogonadism - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Targets, H1 2016 37 Number of Products by Stage and Targets, H1 2016 37 Number of Products by Top 10 Mechanism of Actions, H1 2016 39 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 39 Number of Products by Routes of Administration, H1 2016 41 Number of Products by Stage and Routes of Administration, H1 2016 41 Number of Products by Molecule Types, H1 2016 43 Number of Products by Stage and Molecule Types, H1 2016 43

Antares Pharma, Inc. Clarus Therapeutics, Inc. Diurnal Limited EndoCeutics, Inc. Ferring International Center S.A. Forendo Pharma Limited Lipocine Inc. M et P Pharma AG Merck & Co., Inc. Mereo Biopharma Group Limited Millennium Pharmaceuticals, Inc. Monosol Rx, LLC Pantarhei Bioscience BV Repros Therapeutics Inc. Variant Pharmaceuticals, Inc.